Hello, everyone. Thank you for joining us and welcome to the Sencora Inc. Q3 Fiscal Year 2026 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Bennett Murphy. Bennett, please go ahead.

Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Sincorra's fiscal 2026 third quarter results. I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob Motch, President and CEO, and Eva Barato, Executive Vice President and CFO. On today's call, we will be discussing non-GAAP financial measures. Reconciliations of these measures to GAAP are provided within today's press release which is available on our website at investor.sincora.com. We've also posted a slide presentation to accompany today's press release on our investor website. During this conference call we will discuss forward-looking statements about our business and financial expectations on an adjusted non-GAAP basis including but not limited to EPS operating income and income taxes. Forward-looking statements are based on management's current expectations and are subject to uncertainty and change. For discussion of key risks and assumptions we refer you to today's press release and our SEC filings, including our most recent 10Q. Sancora assumes no obligation to update any forward-looking statements, and this call cannot be rebroadcast without the permission of the company. You have the opportunity to ask questions after today's remarks by management. We ask that you limit your questions to one per participant in order for us to get to as many as possible within the hour. With that, I'll turn the call over to Bob.

Thank you, Bennett. Hi, everyone, and thank you for joining Sancora's fiscal 2026 third quarter earnings call. To start, I'd like to thank our Sencora team members for their continued commitment to providing valuable solutions for our customers. In our third quarter, we delivered strong results driven by execution across Sencora and investments to advance our specialty positioning and our pharmaceutical-centric strategy. Our business performance drove double-digit adjusted operating income growth, and supported by $1 billion of opportunistic share repurchases, we achieved 12% EPS growth in the quarter. We're pleased to be raising our fiscal 2026 EPS guidance, reflecting our confidence in our continued execution and the strength of our portfolio as we close out the fiscal year. I'm very happy Eva Barato has joined us as Chief Financial Officer. She will provide details on our performance and continued confidence in our short and long-term expectations. During my remarks today, I'll highlight how our strategy enables us to deliver on our growth priorities. First, our differentiated specialty pharmaceutical platform uniquely positions us to support innovation and patient care across our footprint. Second, through our digital transformation, we are modernizing how we operate and serve our partners. And finally, our focus on talent and culture is equipping our teams with the skills, resources, and leadership needed to continue advancing our pharmaceutical-centric strategy and delivering our purpose. I'll start with specialty, where our platform supports growth across the healthcare ecosystem. Our specialty platform builds on our strong foundation in pharmaceutical distribution and deep relationships with providers and manufacturers. Over time, we've expanded our capabilities into a broad set of services designed to address the needs of specialty care. Over nearly three decades, Sancora has worked alongside community providers to advance our distribution, GPO, and practice solutions, helping physicians operate effectively and care for patients close to home. As specialty care has become more complex, these providers are seeking partners who can help them navigate access, reimbursement, and administrative demands while preserving their ability to deliver care in community-based settings. Our management services organizations are well-positioned to help oncology and retina practices manage the growing complexity of specialty care and broaden access to clinical trials and research while allowing physicians to remain focused on patient care. Importantly, our role across the specialty landscape gives us a clear view of what it takes for new therapies to reach patients. That unique perspective informs the work we do with manufacturers who increasingly need partners with the infrastructure, expertise, and connectivity to enable successful launches and protect product integrity. Across Syncora, our specialty logistics, 3PL, and commercialization services help bring innovation to market and drive reliable access to therapies. Before moving to the next topic, I want to reiterate our confidence in the value Sencora provides and our ability to help all stakeholders navigate the impact of market dynamics as we've demonstrated. As the market continues to digest and annualize list price changes, the value proposition of the services we provide remains clear. We're well positioned through our distribution footprint, sourcing scale, and end-to-end channel relationships. Importantly, Part B Biosimilars will continue to be an opportunity for Syncora to drive value for all stakeholders while taking costs out of the healthcare system and improving patient access. Moving to our digital transformation, where we're combining business process improvement and technology advances to improve how we operate and work with partners across the healthcare system. A tangible example of this is our work in demand forecasting. Our teams are using AI to better anticipate product needs across our network and identify key factors driving changes in demand. In a business like ours, these tools help improve planning, enhance product availability, and maintain reliable service for providers, pharmacies, and health systems. Across our organization, we're applying the same discipline approach to simplify routine activities and give our team members better insights. That allows team members to spend less time on manual processes and more time using their expertise to work with partners and solve problems. Next, through our focus on talent culture, we're equipping our teams to continue advancing our pharmaceutical-centric strategy and delivering on our purpose. Across Sancora, our teams bring the expertise and commitment needed to serve providers, manufacturers, and patients in an evolving healthcare environment. We're focused on ensuring our talent has clear career paths while strengthening our ability to execute for customers and partners. That focus extends to key roles across the organization. This quarter, in addition to Eva, we welcome Sam Hammack as Chief Human Resources Officer. Since joining the company, both Eva and Sam have brought valuable expertise and proven to be excellent enterprise leadership team members. I also want to recognize the significant contributions of Jim Cleary and Sylvana Battaglia, who recently retired as CFO and CHRO. Both will continue as advisors through the end of the calendar year. With that, I'll turn the call over to Eva for a discussion of our financial results and updated fiscal 2026 guidance. We're glad to have her here with us today for her first earnings call as CFO.

Thanks, Bob, and good morning, everyone. It's a pleasure to join the call today, and I look forward to engaging with the investor community in the coming weeks and months. Since joining Syncora in June, I've spent time with leaders across the enterprise and deepened my understanding of the strength of our businesses, the durability of our pharmaceutical-centric strategy, and the financial discipline that underpins our long-term growth algorithm. Today, I'll provide an overview of our consolidated fiscal 2026 third quarter results and segment level results before turning to our updated guidance. Unless otherwise stated, my remarks will focus on our adjusted non-GAAP financial results. For further discussions of our GAAP results, please refer to our earnings press release and presentation. Our third-quarter performance reflects the strength of our pharmaceutical-centric strategy, the breadth of our specialty platform, and our disciplined capital deployment. Adjusted operating income grew 17%, driven by strong execution in our U.S. healthcare solution segment, including the performance of our One Oncology acquisition and continued growth in our international segment. while share repurchases also contributed to the 12% adjusted earnings per share growth. Based on our year-to-date performance and confidence in continued execution, we are raising our adjusted EPS guidance for fiscal 2026 to a range of $17.75 to $17.95. Turning now to consolidated revenue, revenue was $84.8 billion, up 5%, driven by growth in both reportable segments and in other, which I will describe in more detail when discussing segment-level results. Moving to gross profit, consolidated adjusted gross profit was $3.5 billion, up 23%, primarily due to growth in the U.S. healthcare solution segment. In the quarter, consolidated gross profit margin expanded by 61 basis points to 4.16%, largely due to our acquisition of One Oncology in February. Consolidated Adjusted Operating Expenses were $2.3 billion, an increase of 27%, which again reflects the impact of the February 2026 acquisition of One Oncology. Excluding both MSOs, Operating Expenses grew 5% on a constant currency basis. Turning now to Operating Income, Consolidated Adjusted Operating Income was $1.2 billion, an increase of 17% compared to the prior year, driven by double-digit growth across both reportable segments and other. Moving now to our Net Interest Expense and Effective Tax Rate for the third quarter. Net interest expense was $141 million, an increase of $59 million compared to the prior year quarter, primarily due to the debt raised in February to finance the One Oncology acquisition. We have made significant progress on our debt repayment commitments and have fully paid off our RCA financing-related term loan balance of $800 million, $400 million repaid in the June quarter, and an additional $400 million repaid in July. Our effective income tax rate was 19.9% compared to 20.7% in the prior year quarter. Finally, diluted share count was 193.9 million shares, a 0.7% decrease compared to the prior year quarter as a result of $1 billion of share repurchases in the quarter at an average price of $268 per share. Regarding our cash balances and adjusted free cash flow, we ended June with $2.8 billion of cash and had strong free cash flow generation, which results in year-to-date adjusted free cash flow of $1.1 billion. Our full-year adjusted free cash flow guidance of approximately $3 billion remains unchanged. Now, I'll turn to our segment results for the third quarter and key drivers of our performance, starting with the U.S. Health Care Solutions segment. Our U.S. Health Care Solutions revenue was $74.9 billion, an increase of 5%. In the quarter, our revenue growth was supported by strength in specialty across both health systems and physician practices. We also saw continued growth in sales of GLP-1s, which increased by $2.3 billion year-over-year. The growth was offset by three items. First, manufacturer list price reductions that represented a $2.4 billion headwind to revenue growth. Second, the 2025 loss of an oncology customer. And lastly, lower sales to our large mail order customer as expected and consistent with second quarter. Moving now to operating income, U.S. healthcare solution segment operating income increased 16% to $966 million. In the quarter, we saw strong growth in specialty across our MSOs, health systems, and community provider businesses. We were particularly pleased with the performance of our MSO platform, with both One Oncology and RCA performing ahead of our expectations. Our core business continued to demonstrate its strength and value, delivering double-digit organic operating income growth when excluding the One Oncology contribution and the loss of the oncology customer last July. I'll now turn to our International Health Care Solutions segment. International Health Care Solutions revenue was $7.7 billion, up 6% on both an as-reported and constant currency basis, driven by growth in our European distribution and specialty logistics businesses, World Courier and European 3PL. In the quarter, International Healthcare Solutions operating income was $166 million, up 21% on an as-reported basis and up 23% on a constant currency basis. In the quarter, our European distribution business continued to benefit from the shift in timing of manufacturer price adjustments in a developing market country, again in the third quarter. And there was strength across our global specialty logistics and European 3PL businesses that delivered double-digit operating income growth. Moving to other, which reflects the businesses for which we are pursuing strategic alternatives, revenue in other was $2.3 billion, up 7%, largely due to growth at Pro Pharma and MWI Animal Health. Operating income was $109 million, up 25% due to operating income growth at MWI Animal Health, which also benefited from being accounted for as held for sale. That completes the review of our segment-level results. I'll now discuss our updated fiscal 2026 guidance. Driven by our strong performance and opportunistic share repurchases, we are pleased to raise our full-year adjusted EPS guidance range to $17.75 to $17.95, up from $17.70 to $17.90. There is no change to our full-year guidance for consolidated or U.S. healthcare solutions revenue. As you continue to refine your models for our full-year U.S. revenue, we would expect revenue to be in the lower half of our 4% to 6% growth range, given current expectation. In the international healthcare solutions segment, we now expect revenue growth to be approximately 8% at the low end of our previous range as a result of the stronger dollar in the second half of the year. On a constant currency basis, we expect international healthcare solution segment revenue growth to be approximately 7%. In other, we anticipate revenue growth of approximately 6%. Moving to operating income, we are raising the bottom end of our guidance for consolidated operating income growth and now expect growth to be in the range of 13% to 14%. At a segment level, we now expect U.S. healthcare solution segment operating income growth to be in the range of 14.5 to 15.5%. This contemplates continued strong growth in the U.S. healthcare solution segment as we have now fully lapped the loss of the oncology customer, continue to benefit from the One Oncology acquisition and have an easier expense comparison in the fourth quarter. In the International Healthcare Solution segment, we now expect both as reported and constant currency operating income growth to be approximately 9%. In Other, we now expect operating income growth to be approximately 10%, reflecting MWI's strong execution, and performance. Moving now to our below-the-line items, we now expect net interest expense to be approximately $490 million, up from our previous expectations of approximately $485 million, primarily reflecting lower interest income following the $1 billion in share repurchases we completed in the quarter. As a result of these repurchases, we are also updating our expectations for full-year diluted shares outstanding to be approximately 194 million shares. Looking ahead to fiscal 2027, we are currently in the midst of our fiscal 2027 planning process and will provide full fiscal year 2027 guidance on our November earnings call. That said, I wanted to offer some perspectives as you think about your models. First, as we announced in February, we have reached an agreement to merge MWI Animal Health with Covetris. We are continuing to work through the regulatory process and have no update on timing. However, for modeling purposes, if the transaction were to close at the midpoint of our fiscal year, we would have a $150 million operating income headwind within other. Given the structure of the transaction that includes upfront cash, preferred equity, and common equity, it would partially offset the earnings headwind netting to an EPS headwind of approximately $0.35. Second, we do not have an update on the expected timing of the iSouth retina carve-out acquisition. As a result, we would not suggest incorporating that into the models at this time. Syncor is well-positioned across our core U.S. and international healthcare solution segments, giving us confidence in our long-term guidance. Although I've only been the CFO for a month, I've been impressed by the strength of our talent, the clarity of our strategy, and the dedication to our purpose. As I look to fiscal 2027 and beyond, I'm excited to further Sancor's strong track record of execution and disciplined capital stewardship to drive durable shareholder value creation. Now, I'll turn the call back to Bob for some closing remarks before we move to Q&A. Bob?

Thank you, Eva. To close, we were pleased with our strong third quarter performance, which supports our increased fiscal 2026 guidance as a testament to the power of our pharmaceutical-centric strategy. I look forward to closely working with Eva as we continue building upon our track record of execution, growth, and disciplined capital deployment to deliver on our long-term guidance. Powered by our purpose, we continue to execute against our growth priorities and performance drivers, positioning Sancora to deliver sustainable long-term value creation. As we look ahead, we remain confident in our ability to deliver continued growth in our U.S. and international healthcare solution segments consistent with our long-term guidance, and we look forward to sharing our 2027 outlook on the November call. We'll now open the call for questions.

We will now begin the question and answer session. Please limit yourself to one question and one follow-up. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Lisa Gill with J.P. Morgan. Your line is open. Please go ahead.

Thanks very much, and thanks for taking the question. Good to hear your voice, Eva. Just really want to understand two things a little bit better. One, would this be the reacceleration that we saw in the U.S. pharma business for, you know, last quarter growing roughly 6 percent, this quarter growing double digits? Can you maybe just give a little more color around what you're seeing? And then secondly, Bob, you did reiterate on fiscal 27, you're comfortable with the long-term view. Just curious if you're comfortable with where the street currently is, which is about 14 percent growth for next year. Are you saying that, you know, that's within the range, or is there anything else that we need to think about beyond the two things that Eva talked about?

Thanks for the question, Lisa, and appreciate your kind words, and I'm super excited to have joined Sancora. And I'll start with your Q3 question. We're really pleased with the performance and the execution in the quarter. On the outperformance, it was largely in the U.S. segment with strength in our MSOs and underlying business trends in the core, with strength in specialty in both health systems as well as physician providers. One Oncology did outperform our expectations, demonstrating the strength of their platform and its ability to attract physicians to the MSO, which we've benefited from overall distribution in GPOs for some time. Excluding the loss, as you said, of Florida cancer and the contribution from One Oncology, our operating income growth was up double digits, a meaningful acceleration from the 7% last quarter. I'll let turn it over to Bob on 2027.

Yeah, thanks, Eva. Hi, Lisa. Thank you for the question. And yeah, we're really excited that Eva is here with us to help us continue to execute at a very high level. You know, on your question about 2027, so Eva gave some modeling guidance that will help, you know, everyone kind of estimate where, you know, we should be for the year. I'm not going to take it any farther than that, but I will reiterate kind of what I was meaning to say in the remarks is that we are confident in our long-term guidance and feel like our execution, the market strength, and the strength of our portfolio will continue to have us within that range.

Your next question comes from the line of Glenn Santangelo with Barclays. Your line is open. Please go ahead.

Oh yeah, thanks and good morning and thank you for taking the question. Hey Bob, I also wanted to follow up on the strength that you saw in the U.S. healthcare operating profit this quarter. And to that end, I wanted to focus a bit more on the specialty business. You know, back in the March quarter, you know, the company called out some weather related disruptions. But this quarter in the prepared remarks, you're specifically calling out RCA and one oncology is doing better than expected, kind of implying that you've seen some reacceleration this quarter. And I want to separate, you know, specialty into part B versus part B, as I think there's a very important distinction here. And I suspect you're going to tell me that part B is the much more meaningful driver. And so maybe could you give us a little bit of additional color here in terms of what you saw in the quarter, I think that'd be helpful. Thanks.

Hey, Glenn. Thanks for the question. It is important on a lot of levels, and I appreciate the opportunity to explain. So we absolutely did call out the acceleration of the businesses in RCA and Warnock, and the market absolutely performed well, and we have these amazing platforms in RCA and One Oncology that certainly we're meeting the needs of patients through that market acceleration, and we believe we'll continue to do so. And Eva can spend a little bit more time on kind of expectations and kind of where we were relative to those. But I do want to spend a minute on the biosimilar part of your question and the kind of Part D versus Part D, because I do think it's important for everyone to understand how we think about it. I'll start with Part D, and well, maybe I'll start with biosimilars are good. Biosimilars are good for patients. They're good for cost. They're good for patient access, and so anywhere in our business, it's an incremental positive from a profit standpoint. In Part D, it's less so because we provide less services, less wraparound services in the Part D space when a product goes from an innovator brand to a biosimilar. And as we saw last quarter with our large mail order customer, that may be insourced. And so then we have the revenue decrease, but not a meaningful profit increase. So when we think about the Part D space, biosimilars are good, incrementally positive. for Part B, it's much more important, as you alluded to. And that is because the Part B buy-and-bill infusion space, which is where our MSOs, where our distribution and GPOs have such a long history of supporting physicians. And within that history, and I talked about distribution, GPO, and the MSO, and when we talk about wraparound services, those are all the things that we do to support those products coming to market from a physician perspective, I mean, from a manufacturer perspective, and then support the physicians in understanding how they may choose to use those products. So that's, therefore, there's a larger profit opportunity because we play a bigger role in how they're assessed and utilized. So we should think, again, kind of But all the way back, biosimilars are good for Sancora. Part D, much less so, but still good, even though we'll have revenue pressure from time to time with those switches. But Part B will always be good, and we feel very confident about the durability of that over the long term.

Your next question… And just to add on…

Eva, why don't you go ahead.

Just to add on the utilization trends, right, we did see a sequential rebound in the utilization trends from the March quarter, strong sales and specialty products, as I said previously, to health systems and physician providers. Oncology clearly is the larger, but retina also contributed to that sequential improvement.

Your next question comes from the line of Elizabeth Anderson with Evercore ISI. Your line is open. Please go ahead.

Hi, guys. Thank you so much for the question, and welcome, Ava. Nice to hear you on the call. Could you talk about the operational improvements you're seeing in the One Oncology business, and sort of where do you think you are in the integration efforts, and sort of how do we think about this to help us understand the sustainability of that above average growth rate going forward.

Yeah. Hi, Elizabeth. It's Bob. I'll start that and then I'll hand it over to Eva. So as we've explained, there really are three phases to the value creation thesis that we have for the MSOs. One is the integration of those MSOs into Syncora. So We have significant progress on RCA, good progress on OneOncology, and that's working very well. So the value that Sancora can provide to those businesses we're providing, and as we've talked about, you're seeing the results of their performance. The second phase is where we will share capabilities across the platform. And, you know, the example that we've used, you know, throughout is the clinical trial space. And I would say we're still early days there in kind of that phase two of sharing capabilities. On track, we feel good about where we are, but still early days there. And then the third phase is where we will be developing new services. So the excellent capabilities that we have at Sancora from a corporate standpoint, And then also within the MSOs of RCA and One Oncology, where we'll build new solutions for both physicians and for pharmaceutical manufacturers. So you can think about analytics-type solutions and insights that we'll be providing. But that's in the future and then in Phase 3. And all of that is underpinned by the continuous addition of physicians to both platforms. And those additions come in the form of tuck-ins that will happen within either and both of the platforms. And it also happens with individual physicians joining the platform, whether they're recently out of fellowship or moving from another side of care to the community setting. So all of that is working well. I would say we're on track. you see the results of that, but still early days in terms of the value creation that we believe that we can create. And I'll hand it over to Eva.

Great. Thanks, Bob. And good morning to you as well, Elizabeth. As Bob said and I said earlier, both One Oncology and RCA continue to perform well, and we're very pleased with these platforms. I'll go a little deeper on One Oncology. As you think about it on a 12-month basis, we continue to expect One Oncology to be neutral from an adjusted earnings per share net of financing. I would also note, as we continue to evaluate One Oncology's accounting for its UUG subsidiary as it relates to non-controlling interest, In the third quarter, we determined that there should not be a non-controlling loss add back to net income. There was no impact to operating income from this change. You know, it's a complex area. So looking beyond this pretty modest accounting item, overall, one oncology operating income is modestly better than our initial expectations.

Your next question comes from the line of Alan Lutz with Bank of America. Your line is open. Please go ahead.

Good morning, and thanks for taking the questions. I want to follow up on the strength in the U.S. healthcare solutions business. I think if we look at the sequential improvement and growth, you talked about, well, obviously weather was an impact in 2Q. I think if you X that out, the rebound was may be a little bit stronger than we expected. Is there anything else to call out as you think about the pockets of strength from your fiscal 2Q or that calendar 1Q quarter going in the calendar 2Q? Was there any one-time dynamic around the IRA that impacted 1Q that is now normalized? Trying to understand if there's anything there that was maybe one time in that calendar 1Q that may be abating now. And then just a quick follow-up, do any of the changes going on in 340B have any impact on your business? Thanks.

Yeah, thanks for the question. For fiscal quarter Q2 to Q3, really the driver of the acceleration was the underlying strength in the utilization, as we called out relative to the prior quarter. I would also note, you know, as you look forward to Q4, our Q4 implied guidance also implies strong double-digit growth across our reportable segments. And as you think about that in the U.S., we'll have fully lapped the one oncology customer loss and will have an easier expense comp. But when excluding One Oncology, we expect to see the strongest organic growth of the year at the midpoint of our guidance. So just underlying continued momentum of the business, strengthen international as well. And I'll turn it over to Bob for the 340B.

Thanks for the questions. And, you know, I just want to reiterate what Eva was saying with, you know, the ramp is happening just as we planned. So as we talked about, you know, the second quarter being our lowest growth quarter, which it was, and we talked about the ramp that we had in the second half of the year and got a lot of terrific questions about how we were going to do that. But, you know, as you heard, we had a lot of confidence. It was mechanical, not aspirational, and, you know, we continue to see the opportunities there. On 340B, Alan, as you know, you know, there's recently been, you know, guidance on the 340B program test that will be out there. We're still assessing it. As you know, we stay very close to all things policy, spend a lot of time in Washington. So we will participate in continuing to monitor talking to regulators and legislators about potential unintended consequences. And our focus in all these discussions is always patient access and having the most efficient access to care. Thank you for the question.

Your next question comes from the line of Charles Rai with T.D. Cohen. Your line is open. Please go ahead.

Yeah, thanks for taking questions. And Eva, great to hear you again. Bob, you know, when you talked about one oncology earlier, you talked a little bit about opportunities, particularly in research and clinical trials. You know, I think that's a – maybe can you talk a little bit about how much of that is already being done by One Oncology? You know, maybe how much of revenues or maybe some qualitative estimate of how important that is today and, you know, how mature is that as an opportunity for One Oncology? Because, you know, is this – maybe are we still like in early innings? And how big of an opportunity do you think that could really be?

Hey, Charles. Thank you for the question. Uh, it's, uh, it's, uh, I'll connect one oncology and RCA together, uh, and, uh, kind of the, the answer of what inning we're in, it, it varies depending on which part of the, uh, MSO platform, uh, that you are. So, uh, one, uh, as we expand the, uh, clinical trial business within the MSOs, it's, it's an absolute, uh, driver of profitability and growth. Uh, RCA, is mature in the space. So they've built a significant, well-respected platform that pharmaceutical manufacturers depend on when getting clinical trials done in the retina space. There is a meaningful clinical trial activity within one oncology, but there's significant opportunity for growth. So I would say to use your innings analogy, I think we're kind of in the later innings of the build-out of RCA. Now, remember, the growth continues because products are always coming for clinical trials. So that doesn't mean that the growth slows, but the maturity of the build-out is in the latter innings. In one oncology, it's in the earlier innings, which is why we have so much optimism about the opportunity. Obviously, the amount of innovation in the oncology space and the need for clinical trial support will only continue to grow and will be a great source of that. And just to add, and this is true for RCA and N1 Oncology, the community specialty physician side of care we talk about as being the most cost-effective side of care in almost all cases, but it's also the most accessible side of care. So, having meaningful clinical trial access within the community physician space means that more patients will have access to those trials, which is really important for their healthcare and also for the accrual of the trials, which is one of the biggest challenges that the manufacturers have. Thank you for the question.

Your next question comes from the line of George Hill with Deutsche Bank. Your line is open. Please go ahead.

Good morning, guys. Thanks for taking the question. And Eva, again, welcome back to the healthcare services space. I guess I have kind of two quick ones I'd like to bounce through is number one on the World Courier and the 3PL business. It seems like there's been a step up in competitiveness in that market over the last 12 months. Would just appreciate if you could comment on anything you've seen there. And then as it relates to kind of the Q4 guidance, like, and as it relates to specialty in oncology with the pricing dynamics, there also seems to be a little bit of a dollar-based slowdown in the market given drug pricing and a little bit of a utilization slowdown just would be interesting in any, if kind of a slowdown in the oncology market is weighing on kind of the Q4 results and the Q4 guidance in the U.S. business.

Yeah. Hey, George, I'll take the first party question that I'll hand over to to Eva for for the second. So we are really well positioned in the specialty logistics and 3PL space. So remembering, and you know well, George, our World Courier business is the highest and specialized logistic services for pharmaceutical manufacturers, primarily with clinical trials. And we have differentiated capabilities that have been there over a long period of time. Within our 3PL business, the European part of the 3PL business came with the Alliance Healthcare acquisition. We have a U.S.-based part of that business called ICS, who also have very specialized capabilities for specialty product movement. So I start with our capabilities, and that leads to differentiation because, George, there certainly are other players who are building healthcare, 3PL, logistics capabilities, very credible players. We play at a higher end of those services and also find that the pharmaceutical manufacturers often prefer someone who is health pharmaceutical focused. And, you know, we talk about our pharmaceutical centric strategy. That also is true for our 3PL, especially logistics. So when we're talking to pharmaceutical manufacturer, we're talking about capabilities, but also our expertise in the pharma channel, which allows us to compete very well, even though there are, you know, well-known, credible competitors in the space we continue to grow. And I'll hand it over to Eva.

Great. Thanks, Bob. So good morning, George, and nice to hear your voice again. Listen, we've seen good utilization trends in specialty, including oncology, as part of the market that we saw consistent growth throughout Q3, and it's continued to be a long-term growth driver. As you see by our implied 4Q guidance, right, there's a sequential improvement, the U.S. performing the strongest organic growth in the segment at the midpoint of our guidance, so we're pleased with the underlying performance and the trends we're seeing.

Your next question comes from the line of Kevin Caliendo with UBS. Your line is open. Please go ahead.

Thanks. Thanks for taking my question. And Ava, good to hear from you again. My question is around some of the proposed changes in the ASP rules that came out recently and just how you're thinking about it or how we should think about it as a potential risk going forward or not a risk at all. Have you sort of explored how this might change ASPs and how to think about that for your MSO business or your GPO, and if there's any way to sort of quantify it at this point.

Yeah. Hey, Kevin, thank you for that important question. So, yeah, we spend a lot of time evaluating and studying all of the policy ideas that are out there and how that may or may not impact ASP risk. And where we land in all cases is that the policies that are under consideration or being tested are not intended to impact physician reimbursement. You know, I've talked about today, we talk about often the community physician being the most accessible and the lowest cost site of care. And any policy that would negatively impact those physicians would impact their ability to care for patients and therefore decrease access for patients to those important physicians. So that's what we, when we're in Washington, those are the types of things that we talk about. And it's all about patient access and cost effectiveness within the healthcare system, which is where these community specialists really differentiate themselves. So how that plays through is you see things like in the Globe demonstration project that any discounts that are paid from the manufacturer to the government actually are not going to flow through reimbursement or impact ASP. They're going to be adjudicated in a direct payment from the manufacturer to the government. So that is recognition that the policymakers understand the risk to impacting community physician reimbursement. I think it also demonstrates the fact that they do not want to do that and they're therefore testing an alternate mechanism. So Kevin, it's an important question is something that we spend a lot of time on, but we do feel confident that as this plays out and as we get to 2028 in particular with IRA and Part B, that the reimbursement to physicians will not be negatively impacted. Thanks for the question.

Your next question comes from the line of Erin Wright with Morgan Stanley. Your line is open. Please go ahead.

Great. Thanks. I have a quick two-parter. So just in the context of what you were just talking about with the ASP changes and pricing dynamics from a regulatory perspective, do you anticipate that in that context you can still invest more and lean more into the MSO businesses? I know there's not much left to do in oncology world on MSO side, but otherologies, you know, in the context of everything from a regulatory perspective. Is the biosimilar opportunity there, for instance, disproportionately greater in some of those certain areas? And then just quickly, Eva, looking forward to working with you again. Since you've come on board, I guess, any surprises? How do you think about how, you know, any changes in terms of the philosophy around guidance or capital deployment? You know, we're already going through some right sizing across this and core business with some divestitures, but how do you think about the commitment to the various parts of the business, the mix of the business day at this juncture. Thanks.

Hi, Erin. Thanks for the question. I'll take the ASP and MSO question, and then I'll obviously hand it to Eva for your question to her. So, yeah, we feel confident in the long-term outlook for the community position space, and that includes reimbursement over the long-term. So, we do intend to continue to invest in the MSO space. I'll note that our intention is to really focus on tuck-in acquisitions for RCA in the retina space and one oncology in the oncology space. As it pertains to other ologies, we're very happy to service all specialty products in whatever side of care that they're intended to go, and our portfolio of services and customers allows us to do that. But in terms of MSO investment, we intend to stay pharmaceutical centric. So right now, oncology and retina are the only two specialties that we view as pharmaceutical centric per our assessment. And so, you know, you wouldn't see us getting into other disease states in terms of MSOs. And then I would say you never say never, right? Because there could be in the future an area where it would make sense. It would be more pharmaceutical centric. It would be a specialty physician administered. And that is a place that we certainly would look to lead when that happens, but we don't see anything in the near term. So, our focus is on, you know, accretive tuck-in acquisitions within the retina and oncology Thanks for the question. I'll hand it over to Eva.

Good morning, Aaron. Thanks for the question. On the guidance question, I'll start with my philosophies on guidance. I set guidance based on a discipline, internal process, reflective of the businesses, our expectations of the business, and I'm supported by an amazing team here, long tenured, with deep expertise in this business. I will look to continue Sancora's long track record of delivering or exceeding expectations. Now, moving to capital deployment priorities, overall, Sincor has had a great capital allocation strategy that's honestly allowed to continue to invest in key growth initiatives while returning capital to shareholders. So, you know, our capital deployment strategy remains focused on internal investments in the business, strategic M&A, opportunistic share repurchase, as we just did in the third fiscal quarter, and maintaining a reasonable and growing dividend. So overall, I want to build on the framework to enhance our flexibility to invest in the business and drive shareholder value.

And Aaron, I'll just add, you know, I've mentioned in my prepared remarks how excited I am to work closely with Eva, and you just heard one of the reasons why. So our philosophies in terms of how this will go forward are very aligned, very aligned to how we've done things in the past, and our performance and financial discipline has allowed us to have excellent performance and continue to implement and expand our strategy. So I'm looking forward to continuing to work with Eva to do that. Thanks for the question.

Your next question comes from the line of Eric Coldwell with Baird. Your line is open. Please go ahead.

Thanks very much. Most of the more important stuff was covered, but two quick ones, if I might. First, just if I missed it, the held for sale accounting benefit in the other segment, if you could quantify that for us, would be great. And then on GLP-1 sales, I know you said they were up $2.3 billion year over year. That looks like low to mid-20% growth, maybe up low double digits quarter over quarter. I'm curious how that stacked up versus your expectations. And then if you have any thoughts on the GLP-1 bridge program with Medicare. Thanks very much.

Yeah, good morning, Eric. On your health for sale, the benefit of the accounting impact, the majority of the growth in the other segment was driven by the health for sale accounting. Underlying MWI delivered about 10% growth and drove the change to our outlook for the year. In terms of the GLP-1s up 25%, that was generally in line with our expectations.

Your next question comes from the line of Daniel Grossleit with Citi. Your line is open. Please go ahead.

Hi, thanks for taking the question. I want to switch over to the international side a little bit, particularly the European distribution. distribution former for the past two quarters now i was hoping you could give us a little bit more color on which geographies or therapeutic categories are are driving this growth is it broad-based or concentrated in any specific marketer or area and perhaps more importantly as we think about fiscal 27 are there any um apart from it being a more difficult comp period are Are there any things we should be aware of heading into fiscal 27 on European distribution?

So, you cut out there a little bit in the beginning, so I'm going to repeat the question for the benefit of everyone on the call, which it sounded to me as though you're asking, so the past couple of quarters, you know, after the first quarter, we've had higher than expected performance out of the international segment. What are some of the drivers within that segment? Obviously, we called out the European distribution, but Eva, if you could kind of speak to some of those year-over-year drivers in the international segment.

Sure. Thanks for repeating the question. And, Daniel, thanks for the question. In our European business, it continued to benefit from the timing of manufacturer price increases in developing market country, consistent with previous quarters. Now, we wouldn't expect that impact in Q4, given some of the timing changes. In our specialty logistics business, I think Bob hit on this a little earlier, both World Courier and the European 3PL businesses deliver double-digit operating income growth. In 3PL, we had strong renewals. We've been focused on growing our price pipelines, excuse me, that have supported new business wins. And in World Courier, the business saw good momentum following a challenging market in fiscal 25. And the business continues to position itself for continued growth as the market has stabilized.

Your next question comes from the line of Eric Percher with Nefron Research. Your line is open. Please go ahead.

Thank you, Bob, and welcome, Eva. A question relative to the 340B comment earlier. One of your peers in the drug channel commented today that it is a headwind to a business that is more focused on the TPAs and contract pharmacy. Could you remind us your business, the focus on covered entities and on pharma, what you are doing in 340B and what your value prop is to various participants?

Yeah, Eric, thank you for the question. And I would just answer that with just, we have such a broad portfolio of customers who are, you know, all providing amazing care for patients and their stakeholders. And so, you know, if something were to go through and be implemented, there would be, you know, different impacts to different parts of the business, which we haven't really spoken to. But I wouldn't, you know, I wouldn't assume that that's all negative. I think, you know, there would be puts and takes potentially.

And, you know, we're still obviously assessing what could be, and, you know, until there's something implemented, we wouldn't necessarily size it your next question comes from the line of michael cherny with leering your line is open please go ahead good morning thanks for taking the question and eva uh welcome back as well um maybe just one quick question on the current market landscape obviously you talked about some of the dynamics with your large male customer your other large customer has gone through an ownership transition as you think about your current customer construct is it in a place that you want it to be and are there any significant renewals moves anything outside the norm relative to the market that you're currently um exploring or within your purview thanks yeah hey michael uh thanks for the question uh yeah we we are uh you know very happy with our our customer portfolio.

And as I just said, it's very broad. We have a significant presence in really all sites of care. And our goal, as I've said before, is to support patient access. And we're supporting pharmacies and physicians and other providers kind of wherever the patient needs care. Sencora will be making sure that that customer has the product at the right time and at the right price. So we're happy with that. Our relationships with our large customers and our small customers are good, and there's nothing to call out in terms of renewals. Thanks for the question.

This concludes our Q&A session. I will now turn the call back to Bob Mosh for closing remarks.

Thank you. Thanks, everyone, for joining. We're proud of the strong results that we've posted today and our opportunistic repurchase of $1 billion in the quarter. Sancora's delivering on our long-term track record of execution. We're well positioned by a robust specialty business and broad-based scale and solutions. We have confidence in our talent, our value proposition, end-to-end in healthcare solutions, and our ability to continue driving long-term value for all stakeholders. Thanks everyone very much.

This concludes today's call. Thank you for attending. You may now disconnect.